- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Ryan Haumschild Discusses Stakeholder Collaboration to Boost Biosimilar Adoption
Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, tackles how stakeholders can collaborate and utilize market data to effectively boost biosimilar uptake.
Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, tackles how stakeholders can collaborate and utilize market data to effectively boost biosimilar uptake.
Transcript
How can different stakeholders work together to ensure improved biosimilar utilization across disease states?
Haumschild: I think that’s one of the things that we want to continue to expand upon. How do we get good biosimilar use in oncology, but then good biosimilar use in the immunology disease states, such as rheumatology and gastroenterology? And believe it or not, there’s different uptakes between the different disease states. If we’re using biosimilars and we’re extrapolating data to treat patients in the curative intent, how can we not extrapolate data from gastroenterology to rheumatology, and then start to look at interchangeability?
There’s going to be a never-ending appetite for data, and that’s okay because we’re data driven. How can we leverage the experiences we’ve had and the similar outcomes between reference projects and biologics, and move that into the biosimilar space, so that we can make more timely approvals? Not just wait for every single study and every single patient. And also look at switching immunogenicity and feel comfortable moving forward biosimilars across the board.
13 Strategies to Avoid the Nocebo Effect During Biosimilar Switching
December 18th 2024A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared decision-making, to mitigate the nocebo effect in biosimilar switching, emphasizing the need for a multifaceted approach to improve patient perceptions and therapeutic outcomes.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
